Ana San‐Félix

2.9k citations

87 papers · 2.6k indexed · 1 hit paper · h-index 25

Co-authors: Marı́a-José Camarasa Erik De Clercq María‐Jesús Pérez‐Pérez Sonsoles Velázquez Jan Balzarini Anna Karlsson Carlo Federico Perno Rosa Álvarez
Topics: HIV/AIDS drug development and treatment (48 papers)HIV Research and Treatment (40 papers)Carbohydrate Chemistry and Synthesis (18 papers)
Cited by: Virology Infectious Diseases Organic Chemistry
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Biochemistry
Partner nations: Spain Belgium United States

In The Last Decade

Ana San‐Félix

87 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) Analogs: Synthesis and Anti-HIV-1 Activity

1994 700 citations Rosa Álvarez, Sonsoles Velázquez et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Ana San‐Félix

Since Specialization

Citations

This map shows the geographic impact of Ana San‐Félix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana San‐Félix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana San‐Félix more than expected).

Fields of papers citing papers by Ana San‐Félix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana San‐Félix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana San‐Félix. The network helps show where Ana San‐Félix may publish in the future.

Co-authorship network of co-authors of Ana San‐Félix

This figure shows the co-authorship network connecting the top 25 collaborators of Ana San‐Félix. A scholar is included among the top collaborators of Ana San‐Félix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana San‐Félix. Ana San‐Félix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates 2023 ·International Journal of Molecular Sciences ·(unknown),Rana Abdelnabi,Dominique Schols,Johan Neyts,Marı́a-José Camarasa,Federico Gago,Ana San‐Félix	2
2	Pharmacological Elevation of Cellular Dihydrosphingomyelin Provides a Novel Antiviral Strategy against West Nile Virus Infection 2023 ·Antimicrobial Agents and Chemotherapy ·Nereida Jiménez de Oya,Ana San‐Félix,(unknown),Ana-Belén Blázquez,(unknown),Estela Escribano-Romero,Eva Calvo-Pinilla,(unknown),Josefina Casas,Juan‐Carlos Sáiz,María‐Jesús Pérez‐Pérez,Miguel A. Martín-Acebes	7
3	Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors 2022 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),Irene Fernández‐Barahona,(unknown),Rana Abdelnabi,Sam Noppen,Johan Neyts,Dominique Schols,Marı́a-José Camarasa,Fernando Herranz,Federico Gago,Ana San‐Félix	2
4	Peptidoglycan editing in non-proliferating intracellular Salmonella as source of interference with immune signaling 2022 ·PLoS Pathogens ·Sara B. Hernández,Sónia Castanheira,M. Graciela Pucciarelli,(unknown),(unknown),Alberto Paradela,Juan A. Ayala,Sonsoles Velázquez,Ana San‐Félix,Felipe Cava,Francisco García‐del Portillo	17
5	Identification of L. infantum trypanothione synthetase inhibitors with leishmanicidal activity from a (non-biased) in-house chemical library 2022 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),Sonia de Castro,(unknown),Ana San‐Félix,Ernesto Quesada,Federico Gago,Marı́a-José Camarasa,Antonio Jiménez-Ruı́z,Sonsoles Velázquez	4
6	Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid 2019 ·PLoS Pathogens ·Liang Sun,Hyunwook Lee,Hendrik Jan Thibaut,Kristina Lanko,Eva Rivero‐Buceta,Carol M. Bator,(unknown),Kai Dallmeier,Leen Delang,Pieter Leyssen,Federico Gago,Ana San‐Félix,Susan Hafenstein,Carmen Mirabelli,Johan Neyts	25
7	Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum 2019 ·Antiviral Research ·(unknown),Liang Sun,(unknown),Carmen Mirabelli,Leen Delang,Johan Neyts,Dominique Schols,Marı́a-José Camarasa,Ana San‐Félix	9
8	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors 2015 ·European Journal of Medicinal Chemistry ·Eva Rivero‐Buceta,(unknown),Elisa G. Doyagüez,Andrés Madrona,Ernesto Quesada,Marı́a-José Camarasa,María‐Jesús Pérez‐Pérez,Pieter Leyssen,Jan Paeshuyse,Jan Balzarini,Johan Neyts,Ana San‐Félix	33
9	Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers 2015 ·European Journal of Medicinal Chemistry ·Eva Rivero‐Buceta,(unknown),Elena Casanova,Elisa G. Doyagüez,Andrés Madrona,Ernesto Quesada,María‐Jesús Pérez‐Pérez,Raquel Mateos,Laura Bravo,(unknown),Sam Noppen,Evgeny Kiselev,Christophe Marchand,Yves Pommier,Sandra Liekens,Jan Balzarini,Marı́a-José Camarasa,Ana San‐Félix	10
10	Selective inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by a novel family of tricyclic nucleosides 2011 ·Antiviral Research ·(unknown),(unknown),Ernesto Quesada,Els Vanstreels,Dirk Daelemans,Marı́a-José Camarasa,Jan Balzarini,Ana San‐Félix	2
11	Novel N-3 Substituted TSAO-T Derivatives: Synthesis and Anti-HIV-Evaluation 2008 ·Nucleosides Nucleotides & Nucleic Acids ·(unknown),Ernesto Quesada,(unknown),Jan Balzarini,Nicolas Sluis‐Cremer,María‐Jesús Pérez‐Pérez,Marı́a-José Camarasa,Ana San‐Félix	7
12	The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A 2005 ·Molecular Pharmacology ·Johan Auwerx,Fátima Rodrı́guez-Barrios,Francesca Ceccherini‐Silberstein,Ana San‐Félix,Sonsoles Velázquez,Erik De Clercq,Marı́a-José Camarasa,Carlo Federico Perno,Federico Gago,Jan Balzarini	12
13	N-3 Substituted TSAO Derivatives as a Probe to Explore the Dimeric Interface of HIV-1 Reverse Transcriptase 2003 ·Nucleosides Nucleotides & Nucleic Acids ·(unknown),Cristina Chamorro,Sonsoles Velázquez,Erik De Clercq,Jan Balzarini,Marı́a-José Camarasa,Ana San‐Félix	4
14	Site-Directed Mutagenesis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase at Amino Acid Position 138 2001 ·Virology ·Heidi Pelemans,Abram Aertsen,Kristel Van Laethem,Anne–Mieke Vandamme,Erik De Clercq,María‐Jesús Pérez‐Pérez,Ana San‐Félix,Sonsoles Velázquez,Marı́a-José Camarasa,Jan Balzarini	22
15	4″-H-TSAO-T, A NOVEL PROTOTYPE IN THE HIV-1 SPECIFIC TSAO FAMILY 2001 ·Nucleosides Nucleotides & Nucleic Acids ·(unknown),Sonsoles Velázquez,Ana San‐Félix,Erik De Clercq,Jan Balzarini,Marı́a-José Camarasa	4
16	“SECOND GENERATION” OF TSAO COMPOUNDS DIRECTED AGAINST HIV-1 TSAO-RESISTANT STRAINS 2001 ·Nucleosides Nucleotides & Nucleic Acids ·(unknown),Sonsoles Velázquez,María‐Jesús Pérez‐Pérez,M. Luísa Jimeno,Ana San‐Félix,Erik De Clercq,Jan Balzarini,Marı́a-José Camarasa	2
17	Exploring the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives 2001 ·Antiviral Research ·Cristina Chamorro,María‐Jesús Pérez‐Pérez,Fátima Rodrı́guez-Barrios,Federico Gago,Erik De Clercq,Jan Balzarini,Ana San‐Félix,Marı́a-José Camarasa	16
18	Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine. 1996 ·Molecular Pharmacology ·Jan Balzarini,Heidi Pelemans,María‐Jesús Pérez‐Pérez,Ana San‐Félix,Marı́a-José Camarasa,Erik De Clercq,Anna Karlsson	23
19	Synthesis and Anti-HIV Activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] Dimers as Potential Multifunctional Inhibitors of HIV-1 Reverse Transcriptase 1995 ·Journal of Medicinal Chemistry ·Sonsoles Velázquez,Rosa Álvarez,Ana San‐Félix,M. Luísa Jimeno,Erik De Clercq,Jan Balzarini,Marı́a-José Camarasa	41
20	Biochemical and kinetic characteristics of the interaction of the antitumor antibiotic sparsomycin with prokaryotic and eukaryotic ribosomes 1991 ·Biochemistry ·Ester Lázaro,(unknown),Ana San‐Félix,H. C. J. OTTENHEIJM,Juan P. G. Ballesta	25

About Ana San‐Félix

Ana San‐Félix is a scholar working on Virology, Infectious Diseases and Organic Chemistry, having authored 87 papers that have together received 2.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (40 papers) and Carbohydrate Chemistry and Synthesis (18 papers). The work is most often cited by research in Virology (831 citations), Infectious Diseases (1.1k citations) and Organic Chemistry (1.5k citations). Ana San‐Félix has collaborated with scholars based in Spain, Belgium and United States. Frequent co-authors include Marı́a-José Camarasa, Erik De Clercq, María‐Jesús Pérez‐Pérez, Sonsoles Velázquez, Jan Balzarini, Jan Balzarini, Anna Karlsson, Carlo Federico Perno, Rosa Álvarez and Stefano Aquaro. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact